GlassScriptPhysician profile
Wenyang Li
NPI 1467957274
$3,389.00
in general payments reported to CMS, 2019-2025
20 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $398 · 2023: $1,565 · 2024: $844 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,991.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $601.68 | 2023-2024 | |
| Emd Serono, INC. | $361.81 | 2023 | Mavenclad, Bavencio |
| Pfizer INC. | $329.35 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $237.82 | 2022-2023 | Andexxa |
| Medtronic, INC. | $163.01 | 2022 | |
| Livanova USA, INC. | $156.33 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Incyte Corporation | $126.79 | 2025 | Monjuvi |
| Janssen Biotech, INC. | $124.99 | 2023 | Darzalex, Carvykti, Tecvayli |
| Fresenius Kabi USA, LLC | $124.76 | 2025 | Smoflipid |
| Novartis Pharmaceuticals Corporation | $123.58 | 2023 | |
| Beone Medicines USA, INC. | $122.11 | 2025 | Tevimbra |
| Mirati Therapeutics, INC. | $122.08 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $117.93 | 2022 | |
| Amgen INC. | $117.61 | 2024 | |
| Emmaus Medical, INC. | $117.55 | 2023 | Endari |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $116.36 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $109.01 | 2025 | Lynozyfic |
| Merck Sharp & Dohme LLC | $99.26 | 2024 | Keytruda |
| Btg International INC. | $99.03 | 2025 | Voraxaze |
| Acadia Pharmaceuticals INC | $17.94 | 2023 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wenyang Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.